Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: Phase I dose-escalation study of safety, effi cacy, and immune activation (PIVOT-02)

Adi Diab, Nizar M. Tannir, Salah Eddine Bentebibel, Patrick Hwu, Vassiliki Papadimitrakopoulou, Cara Haymaker, Harriet M. Kluger, Scott N. Gettinger, Mario Sznol, Scott S. Tykodi, Brendan D. Curti, Mary A. Tagliaferri, Jonathan Zalevsky, Alison L. Hannah, Ute Hoch, Sandra Aung, Christie Fanton, Ahsan Rizwan, Ernesto Iacucci, Yijie LiaoChantale Bernatchez, Michael E. Hurwitz, Daniel C. Cho

Research output: Contribution to journal › Article › peer-review

151 Scopus citations

Fingerprint

Dive into the research topics of 'Bempegaldesleukin (NKTR-214) plus nivolumab in patients with advanced solid tumors: Phase I dose-escalation study of safety, effi cacy, and immune activation (PIVOT-02)'. Together they form a unique fingerprint.

Medicine & Life Sciences